Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Personalized oncology in interventional radiology.
Abi-Jaoudeh N
,
Duffy AG
,
Greten TF
,
Kohn EC
,
Clark TW
,
Wood BJ
.
???displayArticle.abstract???
As personalized medicine becomes more applicable to oncologic practice, image-guided biopsies will be integral for enabling predictive and pharmacodynamic molecular pathology. Interventional radiology has a key role in defining patient-specific management. Advances in diagnostic techniques, genomics, and proteomics enable a window into subcellular mechanisms driving hyperproliferation, metastatic capabilities, and tumor angiogenesis. A new era of personalized medicine has evolved whereby clinical decisions are adjusted according to a patient's molecular profile. Several mutations and key markers already have been introduced into standard oncologic practice. A broader understanding of personalized oncology will help interventionalists play a greater role in therapy selection and discovery.
Adams,
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
2011, Pubmed
Adams,
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
2011,
Pubmed
Annunziata,
Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.
2010,
Pubmed
Awada,
Personalized management of patients with solid cancers: moving from patient characteristics to tumor biology.
2012,
Pubmed
Ballestrero,
Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond.
2012,
Pubmed
Bhakta,
Myocardial stunning following combined modality combretastatin-based chemotherapy: two case reports and review of the literature.
2009,
Pubmed
Bilbault,
Life-threatening cervical necrotizing fasciitis after a common dental extraction.
2008,
Pubmed
Black,
Personalized medicine in metastatic non-small-cell lung cancer: promising targets and current clinical trials.
2012,
Pubmed
Bokemeyer,
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
2011,
Pubmed
Burris,
Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer.
2011,
Pubmed
Cheng,
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
2009,
Pubmed
Cheson,
Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma.
2008,
Pubmed
Chung,
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
2005,
Pubmed
Cronin,
Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology.
2011,
Pubmed
De Mattos-Arruda,
Development of molecular biomarkers in individualized treatment of colorectal cancer.
2011,
Pubmed
DeNardo,
Concepts, consequences, and implications of theranosis.
2012,
Pubmed
Dietel,
Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
2013,
Pubmed
Fatourou,
Adaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications.
2009,
Pubmed
Gasparini,
The paradigm of personalized therapy in oncology.
2012,
Pubmed
Gerlinger,
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
2012,
Pubmed
Gianni,
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
2012,
Pubmed
Hanahan,
Hallmarks of cancer: the next generation.
2011,
Pubmed
Hicklin,
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
2005,
Pubmed
Holubec,
The role of cetuximab in the treatment of metastatic colorectal cancer.
2012,
Pubmed
Hurwitz,
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
2004,
Pubmed
Ilie,
Pitfalls in lung cancer molecular pathology: how to limit them in routine practice?
2012,
Pubmed
Kalia,
Personalized oncology: recent advances and future challenges.
2013,
Pubmed
Kantarjian,
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
2002,
Pubmed
Konecny,
Emerging strategies for the dual inhibition of HER2-positive breast cancer.
2013,
Pubmed
Lee,
Proteomics and biomarkers in clinical trials for drug development.
2011,
Pubmed
Lee,
Feasibility and safety of sequential research-related tumor core biopsies in clinical trials.
2013,
Pubmed
Li,
A review on various targeted anticancer therapies.
2012,
Pubmed
Llovet,
Novel advancements in the management of hepatocellular carcinoma in 2008.
2008,
Pubmed
Llovet,
Molecular targeted therapies in hepatocellular carcinoma.
2008,
Pubmed
Llovet,
Sorafenib in advanced hepatocellular carcinoma.
2008,
Pubmed
McKeage,
Clinical trials of vascular disrupting agents in advanced non--small-cell lung cancer.
2011,
Pubmed
Nair,
Personalized medicine: Striding from genes to medicines.
2010,
Pubmed
Parsons,
An integrated genomic analysis of human glioblastoma multiforme.
2008,
Pubmed
Rosell,
Biomarkers in lung oncology.
2010,
Pubmed
Saijo,
Present status and problems on molecular targeted therapy of cancer.
2012,
Pubmed
Saltz,
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
2008,
Pubmed
Schneider,
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.
2008,
Pubmed
Sengupta,
Hepatocellular carcinoma: important biomarkers and their significance in molecular diagnostics and therapy.
2012,
Pubmed
Subramanian,
Recent advances in lung cancer: summary of presentations from the 47 th annual meeting of the American Society of Clinical Oncology (ASCO) 2011.
2012,
Pubmed
Sudhindra,
Biomarkers, prediction, and prognosis in non-small-cell lung cancer: a platform for personalized treatment.
2011,
Pubmed
Tian,
Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine.
2012,
Pubmed
Toffoli,
The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.
2006,
Pubmed
Toyooka,
Molecular oncology of lung cancer.
2011,
Pubmed
,
Echinobase
Van Cutsem,
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
2011,
Pubmed
Van Cutsem,
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
2012,
Pubmed
Villanueva,
Targeted therapies for hepatocellular carcinoma.
2011,
Pubmed
Vogelstein,
Cancer genome landscapes.
2013,
Pubmed
Yardley,
Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
2011,
Pubmed
